Puriblood Medical Co., Ltd. (TPEX:6847)
Taiwan · Delayed Price · Currency is TWD 77.10
-0.70 (-0.90%)
Aug 19, 2026, 11:16 AM CST
Puriblood Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 80.54 | 82.34 | 110.67 | 125.27 | 137.44 | 54.59 | |
Revenue Growth | -31.36% | -25.61% | -11.65% | -8.86% | 151.79% | 41.25% |
Cost of Revenue | 62.66 | 50.03 | 49.52 | 118.75 | 78.78 | 48.99 |
Gross Profit | 17.88 | 32.31 | 61.16 | 6.52 | 58.67 | 5.6 |
Selling, General & Admin | 33.76 | 32.27 | 32.68 | 30.97 | 28.99 | 20.23 |
Research & Development | 31.69 | 33.47 | 31.23 | 25.95 | 22.44 | 20.77 |
Operating Expenses | 65.45 | 65.74 | 63.9 | 56.93 | 51.43 | 40.99 |
Operating Income | -47.57 | -33.44 | -2.74 | -50.4 | 7.24 | -35.4 |
Interest Expense | -1.35 | -1.07 | -0.8 | -1.28 | -1.07 | -0.69 |
Interest & Investment Income | 0.88 | 1.07 | 1.88 | 1.95 | 0.58 | 0.07 |
Earnings From Equity Investments | -4.81 | -6.09 | -1.06 | -0.96 | -0.13 | -0.07 |
Currency Exchange Gain (Loss) | -0.53 | -0.53 | 2.05 | -0.02 | 0.54 | -0.1 |
Other Non Operating Income (Expenses) | 3.74 | 6.06 | 1.73 | 0.03 | -0.12 | 0.07 |
EBT Excluding Unusual Items | -49.64 | -34.01 | 1.04 | -50.68 | 7.04 | -36.12 |
Gain (Loss) on Sale of Investments | -4.75 | -4.75 | -7.03 | -3.75 | 10.05 | -1.9 |
Gain (Loss) on Sale of Assets | - | - | -0.02 | - | -0.15 | - |
Pretax Income | -54.4 | -38.77 | -6.01 | -54.43 | 16.94 | -38.02 |
Income Tax Expense | 1.42 | 0.24 | -0.64 | -2.83 | 0.41 | - |
Net Income | -55.81 | -39 | -5.37 | -51.6 | 16.53 | -38.02 |
Net Income to Common | -55.81 | -39 | -5.37 | -51.6 | 16.53 | -38.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 | 12 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 12 |
Shares Change | -0.00% | - | - | - | 22.10% | 35.52% |
EPS (Basic) | -3.92 | -2.74 | -0.38 | -3.63 | 1.16 | -3.26 |
EPS (Diluted) | -3.92 | -2.74 | -0.38 | -3.63 | 1.16 | -3.26 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -32.66 | -27.87 | -31.74 | 20.4 | -33.04 | -46.83 |
Free Cash Flow Per Share | -2.29 | -1.96 | -2.23 | 1.43 | -2.32 | -4.02 |
Gross Margin | 22.20% | 39.24% | 55.26% | 5.21% | 42.68% | 10.26% |
Operating Margin | -59.06% | -40.61% | -2.48% | -40.24% | 5.27% | -64.84% |
Profit Margin | -69.30% | -47.37% | -4.85% | -41.19% | 12.03% | -69.66% |
Free Cash Flow Margin | -40.55% | -33.85% | -28.68% | 16.28% | -24.04% | -85.78% |
EBITDA | -41.59 | -27.14 | 3.97 | -43.87 | 13.46 | -30.59 |
EBITDA Margin | -51.64% | -32.97% | 3.59% | -35.02% | 9.79% | -56.03% |
D&A For EBITDA | 5.98 | 6.3 | 6.71 | 6.53 | 6.22 | 4.81 |
EBIT | -47.57 | -33.44 | -2.74 | -50.4 | 7.24 | -35.4 |
EBIT Margin | -59.06% | -40.61% | -2.48% | -40.24% | 5.27% | -64.84% |
Effective Tax Rate | - | - | - | - | 2.39% | - |